Uncategorized Archives - Page 4 of 145

ThursdaySep 11, 2025 12:00 pm

Adageis Simplifies Value-Based Care with AI Platform Focused on Financial Gain, Increased Visibility

Adageis provides AI-powered healthcare software designed to simplify value-based care adoption. The company’s patented ProActive Care Platform integrates with leading electronic health record (“EHR”) systems. The platform emphasizes simplicity, visibility into insurance contracts, and long-term financial gain for providers. Providers can use the system to identify high-value services, track reimbursements, and manage complex contracts. Adageis currently covers more than 260,000 patient lives, with ongoing growth expected. Adageis, a growing healthcare technology company with a patented AI-driven platform, is positioning its software as a practical solution for providers seeking clarity in the transition from fee-for-service to value-based care. By focusing on…

WednesdaySep 10, 2025 12:00 pm

HeartBeam Inc. (NASDAQ: BEAT) Advances Power of ECG with High-Fidelity At-Home Heart-Monitoring System

The system’s design emphasizes user friendliness and portability while aligning with the growing trend toward remote patient monitoring and telemedicine. HeartBeam to initiate commercial launch upon FDA clearance of 12-lead ECG synthesis software, anticipated later this year. For decades, the traditional 12-lead electrocardiogram (“ECG”) has been the gold standard in cardiac diagnostics, including arrhythmia assessment, offering a comprehensive assessment of the heart's electrical activity. However, traditional 12-lead ECG systems often come with limitations such as cumbersome setups and restricted accessibility. HeartBeam (NASDAQ: BEAT) is addressing these challenges by developing the HeartBeam System, the first cable-free, high-fidelity ECG system that captures the heart's…

WednesdaySep 10, 2025 9:45 am

Nutriband Inc. (NASDAQ: NTRB): When Market Confidence Validates Scientific Innovation

Recent warrant exercises at $6.43 generated $5.3 million, signaling investor conviction in AVERSA(TM) Fentanyl ahead of NDA filing AVERSA(TM) is a abuse-deterrent solution for transdermal patches, addressing a longstanding gap in pain management safety Strategic funding positions Nutriband to complete development and FDA submission, targeting $80–200 million in peak U.S. annual sales The pharmaceutical sector is defined by a critical balance between innovation and validation. Breakthroughs can take years of research, but they only achieve true market credibility when investors, partners, or acquirers signal confidence in commercial potential. For companies tackling complex problems like opioid abuse, that validation becomes especially…

TuesdaySep 09, 2025 10:30 am

Soligenix Inc. (NASDAQ: SNGX) Showcases Expanding Rare Disease, Public Health Pipeline in Latest Corporate Presentation

At its core, Soligenix is a late-stage biopharmaceutical company that thrives at the intersection of urgent medical need and scientific innovation. SNGX’s Specialized BioTherapeutics division is anchored by its proprietary HyBryte(TM) (“SGX301”), a novel photodynamic therapy for CTCL. Soligenix’s Public Health Solutions division positions the company as an important contributor to biodefense and emerging infectious disease. Soligenix (NASDAQ: SNGX) has taken a bold step forward with its latest corporate presentation, offering investors and the broader biotech community a deeper look into the company’s evolving strategy and pipeline (https://ibn.fm/YGu4N). The presentation underscores Soligenix’s dual focus: pioneering therapies for rare diseases that…

MondaySep 08, 2025 11:15 am

Nutriband Inc. (NASDAQ: NTRB) CEO Showcases AVERSA(TM) Abuse Deterrent Transdermal Technology at Emerging Growth Conference

Nutriband sustains itself through multiple revenue-generating subsidiaries At the core of the company’s innovation is the AVERSA(TM) platform, a proprietary abuse-deterrent transdermal technology AVERSA(TM) fentanyl is projected to achieve peak annual sales of $200 million upon FDA approval, with upside potential exceeding $800 million The opioid crisis continues to highlight the urgent need for safer, more secure drug delivery methods, and Nutriband (NASDAQ: NTRB) is positioning itself as a company with a solution. At the August 2025 Emerging Growth Conference, Nutriband founder and president Serguei Melnik detailed the company’s lead product, AVERSA(TM), an abuse-deterrent transdermal technology that integrates aversive agents…

MondaySep 08, 2025 10:30 am

Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF): Advancing Dedicated Breast Imaging at a Market Crossroads

IzoView Breast CT designed as the first breast-dedicated CT imaging system to eliminate tissue overlap and compression limitations specifically for breast cancer screening in patients with dense breast tissue Platform model supports multiple future clinical applications, including diagnosis and treatment planning without hardware replacement Regulatory pathway alignment and commercialization planning position Izotropic for potential market entry into a $8.7B global breast imaging sector Imaging’s Stagnation Meets a New Wave of Purpose-Built Devices For decades, breast cancer screening has relied heavily on mammography, a compression-based modality that, while valuable, carries persistent shortcomings. Dense breast tissue, which affects nearly half of women,…

ThursdaySep 04, 2025 10:30 am

Soligenix Inc. (NASDAQ: SNGX) Advances Rare Disease Treatment with FDA Orphan Designation

The FDA’s orphan drug designation for dusquetide follows encouraging phase 2a clinical trial results demonstrating both biological efficacy and a favorable safety profile. CEO notes that “the FDA's decision to grant orphan drug designation to the SGX945 program signifies an important step for Soligenix.” Phase 2a pilot data demonstrated clinically meaningful improvements in oral aphthous ulcer healing. Soligenix (NASDAQ: SNGX) has taken a decisive step forward in the fight against rare diseases, announcing that the FDA has granted orphan drug designation to its investigational therapy dusquetide for the treatment of Behçet’s disease (https://ibn.fm/0t1aK). This key FDA designation underscores not only…

WednesdaySep 03, 2025 9:45 am

Oncotelic Therapeutics Inc. (OTLC) Is ‘One to Watch’

The company’s lead candidate, OT-101, is currently in a Phase 3 trial for pancreatic cancer and is advancing toward combination studies with checkpoint inhibitors. A joint venture with GMP Biotechnology enables Oncotelic to conduct low-cost research and development, operate in-house GMP manufacturing, and support a rapidly expanding nanoparticle pipeline trademarked Deciparticle(TM). A strategic partnership with Shanghai Medicilon supports rapid IND filings for up to 20 drug candidates, significantly accelerating development timelines. Oncotelic’s proprietary AI platform, PDAOAI, enhances regulatory and research workflows while offering public engagement tools for added transparency. The company maintains a multi-indication pipeline spanning oncology, Parkinson’s disease, erectile…

TuesdaySep 02, 2025 12:00 pm

Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF): Building Market Awareness Through Strategic Education Platform

BreastCT.com launches as a comprehensive educational resource focused on dedicated breast CT technology and IzoView's clinical advantages for dense breast tissue imaging Platform designed to evolve alongside company progression through clinical studies, regulatory phases, and commercial launch milestones Strategic positioning within successful imaging category creation context provides clear market reference framework for IzoView's commercial potential The Pre-Commercial Challenge: Educating Markets on Breakthrough Technology Medical device companies developing breakthrough technologies face a fundamental commercialization challenge beyond regulatory approval: market education. When innovations represent genuine advances over existing standards of care, successful adoption requires comprehensive stakeholder education across patients, clinicians, and healthcare…

TuesdaySep 02, 2025 9:00 am

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Secures FDA Fast Track for IV Ketamine Formulation NRX-100 in Suicidal Depression

The FDA designation expands the drug’s potential patient pool tenfold, to an estimated 13 million Americans who consider suicide annually. Clinical trials demonstrated rapid and statistically significant reductions in suicidal ideation with IV ketamine versus placebo and comparators. Fast Track status makes NRX-100 eligible for Accelerated Approval and the Commissioner's National Priority Voucher program. NRx is preparing an expanded access policy and seeking meetings with FDA leadership to align on data submission. The U.S. suicidal depression market is estimated at more than $3 billion annually. NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, announced that the U.S. Food and Drug…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Category: Uncategorized

Adageis Simplifies Value-Based Care with AI Platform Focused on Financial Gain, Increased Visibility

HeartBeam Inc. (NASDAQ: BEAT) Advances Power of ECG with High-Fidelity At-Home Heart-Monitoring System

Nutriband Inc. (NASDAQ: NTRB): When Market Confidence Validates Scientific Innovation

Soligenix Inc. (NASDAQ: SNGX) Showcases Expanding Rare Disease, Public Health Pipeline in Latest Corporate Presentation

Nutriband Inc. (NASDAQ: NTRB) CEO Showcases AVERSA(TM) Abuse Deterrent Transdermal Technology at Emerging Growth Conference

Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF): Advancing Dedicated Breast Imaging at a Market Crossroads

Soligenix Inc. (NASDAQ: SNGX) Advances Rare Disease Treatment with FDA Orphan Designation

Oncotelic Therapeutics Inc. (OTLC) Is ‘One to Watch’

Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF): Building Market Awareness Through Strategic Education Platform

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Secures FDA Fast Track for IV Ketamine Formulation NRX-100 in Suicidal Depression

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search